University of Salford
I graduated from The University of Salford in 2005 having completed a BSc Biological Sciences. I went on to do my PhD with Dr Mahesh Nirmalan and Professor David Eisner in the School of Medicine, University of Manchester. The main focus of my work was to investigate the effects of reactive oxygen species (ROS) and proinflammatory cytokines on calcium handling in ventricular myocytes.
Following the award of my PhD in 2009, I took a Post Doctoral position as a cardiac, cellular electrophysiologist with Professor David Eisner and Professor Andrew Trafford in the Institute of Cardiovascular Sciences, University of Manchester. Here, I helped to develop a fluorescent microscopy technique where cells are co-loaded with multiple calcium indicators. This allows the simultaneous, real-time measurement of calcium from multiple sub-cellular compartments. Using this technique, in combination with single cell patch-clamping, I contributed to the understanding of how cardiac intracellular calcium handling is regulated in health, and how this regulation becomes dysfunctional in disease states such as heart failure.
I took up my current position as a Lecturer in Biomedical Science at the University of Salford in September 2014.
Qualifications
BSc (Hons) Biological Sciences, University of Salford, 2005
PhD, University of Manchester, 2009
Memberships
Member of the Physiological Society. Member of the Society of Biology. Member of the European Society of Cardiology (European Working Group For Cardiac Cellular Electrophysiology). Member of the British Society For Cardiovascular Research. Member of the Biophysical Society. Honorary Lecturer, University of Manchester. Physiological Society Representative
“My background is in heart and heart disease-based research. While I am certainly no expert in the field of cancer biology – for example how and why cancer develops and spreads – I am aware of the importance of research that seeks to cure childhood cancer.
At first, it may seem strange that someone who researches the heart is working on a cancer-based project. But by using my expertise in heart-based research, and exploring how anthracyclines affect the heart in cancer patients, I hope to make important contributions to the fight against cancer. My approach is perhaps more indirect. Nonetheless, if my approach adds a new arm to cancer research and reduces the lethal side effects of existing drugs that we know are highly effective against cancer, I share with all cancer researchers a common agenda; reduce the number of lives lost to cancer.”
Dr David Greensmith currently leads a Research Group who are investigating why a class of chemotherapy drugs call anthracylines cause damage the heart in order to prevent this damage in the future.
0161 295 3864 